Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Data Presentations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...
/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...
Press release content from PR Newswire. The AP news staff was not involved in its creation.
- XPOVIO® (selinexor) approvals received in Mainland China, Australia, South Korea and Singapore, expect Hong Kong and Taiwan in remainder of 2022. - 2021 Revenue of RMB28.8 million, Named Patient Program paving way for strong commercial launch in 2022. - Broad and deep clinical program of 18 studies, including 5 registrational studies, ongoing across multiple regions. - Strong cash,...